![Slc11a1 gene polymorphism influences dextran sulfate sodium (DSS)-induced colitis in a murine model of acute inflammation | Genes & Immunity Slc11a1 gene polymorphism influences dextran sulfate sodium (DSS)-induced colitis in a murine model of acute inflammation | Genes & Immunity](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41435-023-00199-7/MediaObjects/41435_2023_199_Fig1_HTML.png)
Slc11a1 gene polymorphism influences dextran sulfate sodium (DSS)-induced colitis in a murine model of acute inflammation | Genes & Immunity
![PDF) The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): The CLL Research Consortium experience PDF) The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): The CLL Research Consortium experience](https://i1.rgstatic.net/publication/293169129_The_Dohner_fluorescence_in_situ_hybridization_prognostic_classification_of_chronic_lymphocytic_leukaemia_CLL_The_CLL_Research_Consortium_experience/links/5a0bf1f2458515e48275027f/largepreview.png)
PDF) The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): The CLL Research Consortium experience
![Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance | Journal of Medicinal Chemistry Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c00030/asset/images/large/jm2c00030_0014.jpeg)
Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance | Journal of Medicinal Chemistry
![Frontiers | Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories Frontiers | Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories](https://www.frontiersin.org/files/Articles/1123029/fonc-13-1123029-HTML/image_m/fonc-13-1123029-g002.jpg)
Frontiers | Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
![PDF) Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients PDF) Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients](https://i1.rgstatic.net/publication/354966383_Cardiovascular_adverse_events_in_patients_with_chronic_lymphocytic_leukemia_receiving_acalabrutinib_monotherapy_pooled_analysis_of_762_patients/links/6155f131e7bb415a5d4393a5/largepreview.png)
PDF) Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection Cancers | Free Full-Text | Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection](https://pub.mdpi-res.com/cancers/cancers-14-00281/article_deploy/html/images/cancers-14-00281-g001.png?1652172831)
Cancers | Free Full-Text | Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection
![PDF) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial PDF) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial](https://i1.rgstatic.net/publication/313014474_Idelalisib_or_placebo_in_combination_with_bendamustine_and_rituximab_in_patients_with_relapsed_or_refractory_chronic_lymphocytic_leukaemia_Interim_results_from_a_phase_3_randomised_double-blind_placeb/links/61fdd5d1a7d76d0f08c010ae/largepreview.png)
PDF) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial
![Cancers | Free Full-Text | Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response Cancers | Free Full-Text | Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response](https://www.mdpi.com/cancers/cancers-13-00257/article_deploy/html/images/cancers-13-00257-g001.png)